. 2019 Sep 4;92(1102):20181031. doi: 10.1259/bjr.20181031

Table 2.

Clinical trials investigating IC addition to CCRT in nasopharyngeal carcinoma

Clinical trials	Recruitment period	Phase	Study arms	Chemotherapy regime	No. of patients	Overall survival	p-value	Progression-free survival	P-value
Hui 2009	2002–2004	II	IC + CCRT	IC: cisplatin 75 mg/m² d1 +docetaxel 75 mg/m² d1, Q3W for two cycles CC: cisplatin 40 mg/m² d1, QW for eight cycles	34	94.1%	0.012	88.2%	0.12
Hui 2009	2002–2004	II	CCRT		31	67.7%	0.012	59.5%	0.12
Fountzilas 2012	2003–2008	II	IC + CCRT	IC: epirubicin 75 mg/m² d1 +paclitaxel 175 mg/m² d1 +cisplatin 75 mg/m² d2, Q3W for three cycles CC: cisplatin 40 mg/m² d1, QW for eight cycles	72	70%	0.89	65%	0.38
Fountzilas 2012	2003–2008	II	CCRT		69	59%	0.89	64%	0.38
Tan 2015	2004–2012	II/III	IC + CCRT	IC: carboplatin AUC = 2.5 d1 +gemcitabine 1000 mg/m² d1, d8 +paclitaxel 70 mg/m² d1, d8, Q3W for three cycles CC: cisplatin 40 mg/m² d1, QW for eight cycles	86	94.3%	0.494	74.9%	0.362
Tan 2015	2004–2012	II/III	CCRT		86	92.3%	0.494	67.4%	0.362
Sun 2016	2011–2013	III	IC +CCRT	IC: cisplatin 60 mg/m² d1 +docetaxel 60 mg/m² d1 +fluorouracil 600 mg/m²/day d1-5, Q3W for three cycles CC: cisplatin 100 mg/m² d1, Q3W for three cycles	241	92%	0.029	80%	0·034
Sun 2016	2011–2013	III	CCRT		239	86%	0.029	72%	0·034
Cao 2017	2008–2015	III	IC +CCRT	IC: cisplatin 80 mg/m² d1 +fluorouracil 800 mg/m²/day d1-5, Q3W for two cycles CC: cisplatin 80 mg/m² d1, Q3W for three cycles	238	88.2%	0.815	82.0%	0.028
Cao 2017	2008–2015	III	CCRT		238	88.5%	0.815	74.1%	0.028
Frikha 2018	2009–2012	III	IC +CCRT	IC: docetaxel 75 mg/m² d1 +cisplatin 75 mg/m² d1 +fluorouracil 750 mg/m²/day d1-5, Q3W for three cycles CC: cisplatin 40 mg/m² d1, QW for seven cycles	42	86.3%	0.059	73.9%	0.042
Frikha 2018	2009–2012	III	CCRT		41	68.9%	0.059	57.2%	0.042
Hong 2018	2003–2009	III	IC +CCRT	IC: mitomycin 8 mg/m² d1 +epirubicin 60 mg/m² d1 +cisplatin 60 mg/m² d1 +fluorouracil 450 mg/m² d8 +leucovorin 30 mg/m² d8, Q3W CC: cisplatin 30 mg/m² d1, QW	239	72%	0.62	61%	0.026
Hong 2018	2003–2009	III	CCRT		240	68%	0.62	50%	0.026

IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy; CC, concurrent chemotherapy;QW, every week; Q3W, every 3 weeks.

3-year survival results are presented, except that the 5 year results are presented for the trial Hong 2018.